Dupixent Granted Priority Review for Atopic Dermatitis in Adolescents
Officials with the FDA have granted Priority Review to dupilumab (Dupixent, Sanofi) for moderate-to-severe atopic dermatitis in adolescent patients aged 12 to 17 years.
Officials with the FDA have granted Priority Review to dupilumab (Dupixent, Sanofi) for moderate-to-severe atopic dermatitis in adolescent patients aged 12 to 17 years, according to a press release.
If approved by the FDA for this indication, dupilumab will be the first systemic biologic medicine to treat adolescents with moderate-to-severe atopic dermatitis, according to Sanofi.
Dupilumab is currently approved in the United States as a treatment for adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In October 2018, the FDA approved dupilumab for use as an add-on maintenance therapy for patients 12 years and older with moderate-to-severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
Sanofi submitted its supplemental Biologics License Application based on phase 3 data evaluating the efficacy and safety of dupilumab monotherapy in adolescent patients.
The trial enrolled 251 patients who were aged 12 to 17 years old with moderate-to-severe atopic dermatitis whose disease could not be adequately controlled with topical medication or for whom topical treatment was medically inadvisable. According to the data, treatment with dupilumab as a monotherapy significantly improved measures of overall disease severity, skin clearing, itching, and certain health-related quality of life measures in adolescents over 16 weeks.
Click to continue reading on Specialty Pharmacy Times.